THE STORY OF SALMOSS BIOTECH
SALMOSS BIOTECH was born as a result of the invention of a new osteoconductive biomaterial in the context of Dr. Muñoz’s doctoral program. This innovation opened up the opportunity for productive and commercial development.
With this inspiration, Dr. Muñoz invited Gastón Dupré and Rodrigo Cereceda to be part of this project establishing SALMOSS BIOTECH in July 2023. Soon after, an important agreement was signed with the Pontificia Universidad Católica de Chile to scientifically validate the modifications to the original product that give Salmoss its unique properties.
In November, SALMOSS BIOTECH was selected by MIT for the exclusive and demanding IDEA2 program in 2024.